Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TRK-130
- Development stage
- Unknown
- Lead developer
- Toray Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
TRK-130 is an orally administered small molecule antagonist of the Transient Receptor Potential Melastatin 8 (TRPM8) channel, currently under development by Toray Industries for the treatment of overactive bladder (OAB). TRPM8 is a cold-sensing cation channel found on afferent nerve fibers in the bladder wall; its activation is thought to contribute to the sensory urgency and detrusor overactivity characteristic of OAB. By blocking these channels, TRK-130 aims to reduce the hypersensitivity of the bladder and improve symptoms such as urinary frequency and urgency. The drug is currently being evaluated in Phase 2 clinical trials in Japan.
02
Targets
DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)MOR (Mu opioid receptor)TRPM8 (Transient receptor potential cation channel subfamily M member 8)
Beyond the preview
Go deeper on TRK-130.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TRK-130.